ImmunityBio, Inc. IBRX
At closeNov 9, 2026, 5:45 PM EST
After hours · Nov 9, 5:45 PM ET
- YTD
- +259.09%
- 1 year
- +233.80%
- Market cap
- 7.54B
- Revenue (ttm)
- 165.79M
- EPS (ttm)
- -0.96
- Shares out
- 1.06B
- Forward P/E
- -96.96
- YTD return
- +259.09%
- 1-year return
- +233.80%
- Volume
- 44.77M
- Avg volume
- 11.33M
- Open
- 7.23
- Previous close
- 8.64
- Day's range
- 6.36 – 7.35
- 52-week range
- 1.95 – 12.43
- Beta
- 0.17
- Analysts
- Strong Buy
- Price target
- 14.25 (+100.4%)
- Earnings date
- Mar 2, 2027
5D -1.15 (-13.92%)
Key statistics
- Enterprise value
- 10.02B
- PEG ratio
- 0.00
- Price / sales
- 45.45
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 93.90%
- Free cash flow
- -186.56M
- Total cash
- 357.37M
- Total debt
- 1.23B
- Return on equity
- 0.00%
- Short % of float
- 30.67%
- 50-day average
- 8.74
- 200-day average
- 7.96
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 14.25
- Target (high)
- 16.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 2, 2027
Expected Mar 2, 2027. Consensus EPS estimate -0.04333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2027 | Dec 30, 2026 | -0.065 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.07 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.08 | -0.22 | -0.14 | -175.00% |
| May 7, 2026 | Mar 31, 2026 | -0.08 | -0.62 | -0.54 | -675.00% |
| Feb 23, 2026 | Dec 31, 2025 | -0.08 | -0.06 | +0.02 | +25.00% |
| Nov 4, 2025 | Sep 30, 2025 | -0.10 | -0.07 | +0.03 | +30.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Jefferies | main | Buy | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 21, 2026 | BTIG | reit | Buy | Buy |
| May 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 5, 2026 | D. Boral Capital | main | Buy | Buy |
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunitybio.com
News
ImmunityBio Reports Wider Quarterly Loss 
ImmunityBio Q3 Adj. EPS $(0.09) Misses $(0.08) Estimate, Sales $48.841M Miss $59.250M Estimate 
ImmunityBio Reports Expanded ANKTIVA Approval And Global Market Expansion Across 35 Countries 
ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors - ImmunityBio Says ANKTIVA Plus BCG Meets Primary Endpoint In Phase 3 NMIBC Trial, Supports Planned FDA Filing
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial 
ImmunityBio Treats First Patient In Europe With ANKTIVA In Combination With Bacillus Calmette-Guérin 
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ 
Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original - ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC
Your note
Sign in to keep a note on IBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADCOCK RICHARD | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 19, 2026 | 560,344 |
| COHEN CHERYL L | Director | Conversion of Exercise of derivative security | Oct 1, 2026 | 100,309 |
| REGAN LAUER | Officer | Conversion of Exercise of derivative security | Feb 19, 2026 | 115,875 |
| SACHS DAVID C | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 19, 2026 | 300,143 |
| SELECKY CHRISTOBEL E. | Director | Conversion of Exercise of derivative security | Jun 30, 2026 | 0 |
| SIMON BARRY J. M.D. | Director | Sale | Oct 4, 2026 | 2,777,790 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 3.22% | 34,083,262 | 242.33M | Jun 29, 2026 |
| State Street Corporation | 2.02% | 21,398,438 | 152.14M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 1.69% | 17,863,911 | 127.01M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.48% | 15,691,579 | 111.57M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 1.09% | 11,551,019 | 82.13M | Jun 29, 2026 |
| Two Sigma Investments, LP | 1.05% | 11,097,106 | 78.90M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.10% | 11,702,382 | 83.20M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.09% | 11,597,491 | 82.46M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.94% | 9,991,183 | 71.04M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.79% | 8,399,273 | 59.72M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.46% | 4,852,894 | 34.50M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.40% | 4,230,859 | 30.08M | Aug 30, 2026 |